Caring Ambassadors Program

Hepatitis C Newsletter


September 2012


Clinical Trials, Cohort Studies, Pilot Studies


Active disease in chronic hepatitis C patients with normal alanine aminotransferase. Arif A, Ahmed W, Alam SE, Qureshi H. J Coll Physicians Surg Pak. 2012 Aug;22(8):488-91.


Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort. Eskesen AN, Melum E, Moghaddam A, et al.. Eur J Gastroenterol Hepatol. 2012 Aug;24(8):890-6.


Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: A randomized trial. Furusyo N, Ogawa E, Sudoh M, et al. J Hepatol. 2012 Aug 10. [Epub ahead of print]


The use of peginterferon in monotherapy or in combination with ribavirin for the treatment of acute hepatitis C. Nunnari G, Montineri A, Portelli V, Savalli F, Fatuzzo F, Cacopardo B. Eur Rev Med Pharmacol Sci. 2012 Aug;16(8):1013-6.


RANTES, TNF-α, Oxidative Stress, and Hematological Abnormalities in Hepatitis C Virus Infection. Tawadrous GA, Aziz AA, Amin DG, Eldemery A, Mostafa MA. J Investig Med. 2012 Aug;60(6):878-82.


Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: does ethnicity matter? Papastergiou V, Dimitroulopoulos D, Skorda L, et al. J Med Virol. 2012 Aug;84(8):1217-23. doi: 10.1002/jmv.23324.


Hepatitis C Virus-Specific Cell-Mediated Immune Responses in Children Born to Mothers Infected with Hepatitis C Virus. El-Kamary SS, Hashem M, Saleh DA, et al. J Pediatr. 2012 Aug 8. [Epub ahead of print]


Early anemia and rapid virological response improve the predictive efficiency of IL28B-genotype for treatment outcome to antiviral combination therapy in patients infected with chronic HCV genotype 1. Amanzada A, Schneider S, Moriconi F, et al. J Med Virol. 2012 Aug;84(8):1208-16. doi: 10.1002/jmv.23323.


Basic and Applied Science, Pre-Clinical Studies


Induction of microRNA-214-5p in human and rodent liver fibrosis. Iizuka M, Ogawa T, Enomoto M, Motoyama H, Yoshizato K, Ikeda K, Kawada N. Fibrogenesis Tissue Repair. 2012 Aug 1;5(1):12. [Epub ahead of print]


Role of the equilibrative and concentrative nucleoside transporters in the intestinal absorption of the nucleoside drug, ribavirin, in wild-type and ent1(-/-) mice. Moss AM, Endres CJ, Ruiz-Garcia A, Choi DS, Unadkat JD. Mol Pharm. 2012 Sep 4;9(9):2442-9. Epub 2012 Aug 3.


Mutations in non-structural 5A and rapid viral response to pegylated interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C. Yano Y, Seo Y, Miki A, et al. Int J Mol Med. 2012 Aug 9. doi: 10.3892/ijmm.2012.1093. [Epub ahead of print]


Focal Adhesion Kinase (FAK) Mediates the Induction of Pro-Oncogenic and Fibrogenic Phenotypes in Hepatitis C Virus (HCV)-Infected Cells. Alisi A, Arciello M, Petrini S, Conti B, Missale G, Balsano C. PLoS One. 2012;7(8):e44147. Epub 2012 Aug 28.


Hepatitis C virus translation preferentially depends on active RNA replication. Liu HM, Aizaki H, Machida K, Ou JH, Lai MM. PLoS One. 2012;7(8):e43600. Epub 2012 Aug 24.


Human Monoclonal Antibody HCV1 Effectively Prevents and Treats HCV Infection in Chimpanzees. Morin TJ, Broering TJ, Leav BA, et al. PLoS Pathog. 2012 Aug;8(8):e1002895. Epub 2012 Aug 30.


Quantifying the Diversification of Hepatitis C Virus (HCV) during Primary Infection: Estimates of the In Vivo Mutation Rate. Ribeiro RM, Li H, Wang S, et al. PLoS Pathog. 2012 Aug;8(8):e1002881. Epub 2012 Aug 23.


Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing. Li H, Stoddard MB, Wang S, et al. PLoS Pathog. 2012 Aug;8(8):e1002880. Epub 2012 Aug 23.


Identification and Targeting of an Interaction between a Tyrosine Motif within Hepatitis C Virus Core Protein and AP2M1 Essential for Viral Assembly. Neveu G, Barouch-Bentov R, Ziv-Av A, Gerber D, Jacob Y, Einav S. PLoS Pathog. 2012 Aug;8(8):e1002845. Epub 2012 Aug 16.


Self-enhancement of hepatitis C virus replication by promotion of specific sphingolipid biosynthesis. Hirata Y, Ikeda K, Sudoh M, et al. PLoS Pathog. 2012 Aug;8(8):e1002860. Epub 2012 Aug 16.


Comparison of Hepatitis C virus subtyping by ns5b sequencing with 5'utr based methods.

Pagani E, Huemer HP, Pasquetto V, Cemin C, Molon L, Rossi P, Larcher C. Minerva Med. 2012 Aug;103(4):293-7.


Patient-Derived Hepatitis C Virus and HCV JFH-1 Clones Differ in Their Ability to Infect Human Hepatoma Cells and Lymphocytes. Sarhan MA, Chen AY, Russell RS, Michalak TI. J Gen Virol. 2012 Aug 1. [Epub ahead of print]


HIV/HCV Coinfection


Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients. Mira JA, Rivero A, de Los Santos-Gil I, et al. AIDS. 2012 Aug 24;26(13):1721-1724.


Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection. Grebely J, Hellard M, Applegate T, et al. AIDS. 2012 Aug 24;26(13):1653-1661.


Health Care Utilization in HIV-Infected Patients: Assessing the Burden of Hepatitis C Virus Coinfection. Norton BL, Park L, McGrath LJ, Proeschold Bell RJ, Muir AJ, Naggie S. AIDS Patient Care STDS. 2012 Sep;26(9):541-5. Epub 2012 Aug 3.


Hepatitis C Virus Infections in the Swiss HIV Cohort Study: A Rapidly Evolving Epidemic.

Wandeler G, Gsponer T, Bregenzer A, et al. Clin Infect Dis. 2012 Aug 14. [Epub ahead of print]


Liver fibrosis progression in HIV/hepatitis C virus coinfected patients with normal amino-transferases levels. Pace FH, Ferreira LE, Silva AE, Ferraz ML. Rev Soc Bras Med Trop. 2012 Aug;45(4):444-7.


Longitudinal analysis of the 5'UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients. Bolcic F, Laufer N, Torres C, Cassino L, Reynoso R, Quarleri J. Antiviral Res. 2012 Aug;95(2):72-81. Epub 2012 Jun 7.


Complementary and Alternative Medicine


Evidence That Naturopathic Therapy Including Cordyceps sinensis Prolongs Survival of Patients With Hepatocellular Carcinoma. Niwa Y, Matsuura H, Murakami M, Sato J, Hirai K, Sumi H. Integr Cancer Ther. 2012 Aug 9. [Epub ahead of print]


Curcumin inhibits HCV replication by induction of heme oxygenase-1 and suppression of AKT. Chen MH, Lee MY, Chuang JJ, Li YZ, Ning ST, Chen JC, Liu YW. Int J Mol Med. 2012 Aug 20. doi: 10.3892/ijmm.2012.1096. [Epub ahead of print]


Epidemiology, Diagnostics, and Miscellaneous Works


Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. MMWR Recomm Rep. 2012 Aug 17;61(RR-4):1-32.


Prevalence and correlates of HIV and HCV infection among amphetamine-type stimulant users in 6 provinces in China. Bao YP, Liu ZM, Lian Z, et al. J Acquir Immune Defic Syndr. 2012 Aug 1;60(4):438-46.


Syringe Acquisition Experiences and Attitudes among Injection Drug Users Undergoing Short-Term Opioid Detoxification in Massachusetts and Rhode Island. Zaller ND, Yokell MA, Nayak SM, Fu JJ, Bazazi AR, Rich JD. J Urban Health. 2012 Aug;89(4):659-70.


Hepatitis B and C Virus Infection Among 1.2 Million Persons With Access to Care: Factors Associated With Testing and Infection Prevalence. Spradling PR, Rupp L, Moorman AC, et al. Clin Infect Dis. 2012 Aug 8. [Epub ahead of print]


Effects of patient factors on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in patients with chronic hepatitis C. Chen SH, Li YF, Lai HC, et al. BMC Gastroenterol. 2012 Aug 10;12(1):105. [Epub ahead of print]


Liver Cancer


From cirrhosis to hepatocellular carcinoma in HCV-infected patients: genes involved in tumor progression. Wang Y, Li J, Chen J, Liu L, Peng Z, Ding J, Ding K. Eur Rev Med Pharmacol Sci. 2012 Aug;16(8):995-1000.


Causes of and prevention strategies for hepatocellular carcinoma. Cabibbo G, Maida M, Genco C, Antonucci M, Camm C. Semin Oncol. 2012 Aug;39(4):374-83.


An analysis of content in comprehensive cancer control plans that address chronic hepatitis B and C virus infections as major risk factors for liver cancer. Momin B, Richardson L. J Community Health. 2012 Aug;37(4):912-6.


Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma. Takeyasu M, Akuta N, Suzuki F, et al. J Med Virol. 2012 Aug;84(8):1199-207. doi: 10.1002/jmv.23288.


An investigation of bloodborne pathogen transmission due to multipatient sharing of insulin pens. Hakre S, Upshaw-Combs DR, Sanders-Buell EE, et al. Mil Med. 2012 Aug;177(8):930-8.


Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study. Izumi N, Asahina Y, Kurosaki M, et al. J Gastroenterol. 2012 Aug 9. [Epub ahead of print]


Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma.

Kuske L, Mensen A, M Llhaupt B, et al. Swiss Med Wkly. 2012 Aug 6;142:0. doi: 10.4414/smw.2012.13651.


Comparative diagnostic efficacy of serum squamous cell carcinoma antigen in hepatocellular carcinoma. Soyemi OM Dr, Otegbayo JA Dr, Ola SO Dr, Akere A Dr, Soyemi T Dr. BMC Res Notes. 2012 Aug 3;5(1):403. [Epub ahead of print]


Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma. Nishida N, Kudo M, Nagasaka T, Ikai I, Goel A. Hepatology. 2012 Sep;56(3):994-1003. doi: 10.1002/hep.25706. Epub 2012 Aug 2.


A comparison of survival and pathologic features of non-alcoholic steatohepatitis and hepatitis C virus patients with hepatocellular carcinoma. Hernandez-Alejandro R, Croome KP, Drage M, et al. World J Gastroenterol. 2012 Aug 21;18(31):4145-9.


Incidence of Hepatocellular Carcinoma among US Patients with Cirrhosis of Viral or Non-Viral Etiologies. Mair RD, Valenzuela A, Ha NB, et al. Clin Gastroenterol Hepatol. 2012 Aug 15. [Epub ahead of print]